These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3516950)

  • 1. Prognostic factors in non-Hodgkin's lymphoma.
    Tubiana M; Carde P; Burgers JM; Cosset JM; Van Glabbeke M; Somers R
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):503-14. PubMed ID: 3516950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial.
    Carde P; Burgers JM; van Glabbeke M; Hayat M; Cosset JM; Somers R; Sizoo W; Qasim MM; Lefur R; Abbatucci JS
    Radiother Oncol; 1984 Dec; 2(4):301-12. PubMed ID: 6395212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm.
    Munck JN; Dhermain F; Koscielny S; Girinsky T; Carde P; Bosq J; Decaudin D; Juliéron M; Cosset JM; Hayat M
    Ann Oncol; 1996 Nov; 7(9):925-31. PubMed ID: 9006743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy].
    Horikoshi N; Inagaki J; Ogawa M
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1878-84. PubMed ID: 6683953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
    Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
    Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: feasibility and preliminary results.
    Cosset JM; Ozanne F; Henry-Amar M; Carde P; Amiel JL; Hayat M; Habrand JL; Tubiana M
    Radiother Oncol; 1985 Feb; 3(2):133-8. PubMed ID: 3838590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
    Jones SE; Miller TP; Connors JM
    J Clin Oncol; 1989 Sep; 7(9):1186-91. PubMed ID: 2671279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972-1985.
    Richards MA; Gregory WM; Hall PA; Dhaliwal HS; Fernandez J; Stansfeld AG; Jones AE; Lister TA
    Hematol Oncol; 1989; 7(1):1-18. PubMed ID: 2909456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases.
    Parlier Y; Gorin NC; Najman A; Stachowiak J; Duhamel G
    Cancer; 1982 Aug; 50(3):401-9. PubMed ID: 7046899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy.
    Bajetta E; Valagussa P; Bonadonna G; Lattuada A; Buzzoni R; Rilke F; Banfi A
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):3-12. PubMed ID: 2455701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC trial non-Hodgkin lymphomas.
    Somers R; Burgers JM; Qasim M; Van Glabbeke M; Duez N; Hayat M
    Eur J Cancer Clin Oncol; 1987 Mar; 23(3):283-93. PubMed ID: 3297719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.